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Abstract
Background: Using killed microorganisms or their parts to stimulate immunity for cancer treatment dates back to
the end of 19th century. Since then, it undergone considerable development. Our novel approach binds ligands to
the tumor cell surface, which stimulates tumor phagocytosis. The therapeutic effect is further amplified by
simultaneous application of agonists of Toll-like receptors. We searched for ligands that induce both a strong
therapeutic effect and are safe for humans.
Methods: B16-F10 murine melanoma model was used. For the stimulation of phagocytosis, mannan or N-formyl-
methionyl-leucyl-phenylalanine, was covalently bound to tumor cells or attached using hydrophobic anchor. The
following agonists of Toll-like receptors were studied: monophosphoryl lipid A (MPLA), imiquimod (R-837),
resiquimod (R-848), poly(I:C), and heat killed Listeria monocytogenes.
Results: R-848 proved to be the most suitable Toll-like receptor agonist for our novel immunotherapeutic approach.
In combination with covalently bound mannan, R-848 significantly reduced tumor growth. Adding poly(I:C) and
L. monocytogenes resulted in complete recovery in 83% of mice and in their protection from the re-transplantation of
melanoma cells.
Conclusion: An efficient cancer treatment results from the combination of Toll-like receptor agonists and phagocytosis
stimulating ligands bound to the tumor cells.
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Background
Cancer immunotherapy based on the stimulation of in-
nate immunity has a long history. W. Coley initiated the
first studies at the end of 19th century, using a mixture
of inactivated bacteria, Gram-positive Streptococcus pyo-
genes with Gram-negative Serratia marcescens - so called
Coley’s toxin [1]. Further improvement of cancer im-
munotherapy based on the use of microorganisms and
their parts was significantly influenced by the discovery
of pathogen associated molecular patterns (PAMPs).
PAMPs allowed for the understanding of mechanisms,
how innate immunity recognizes foreign microorgan-
isms, and how the immune response is triggered. Syn-
thetic PAMPs analogues (mainly agonists of Toll-like
receptors) were synthesized and tested in cancer therapy
[2]. However, the impact of these therapies was not as
strong as expected [3]. Even though agonists of Toll-like
receptors (TLR) stimulate inflammation, we hypothesize
that the infiltrating cells cannot recognize tumor cells as
a target of their attack, because they do not have any
PAMPs on their surface.
This problem was solved in our previous studies [4, 5],
where we described the use of phagocytic receptors ago-
nists anchored to the surface of tumor cells for cancer
immunotherapy. To achieve a sufficiently strong thera-
peutic effect, it was necessary to combine this therapy
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with simultaneous application of lipopolysaccharide
(LPS) – the agonist of TLR4. The obtained synergy re-
sulted in shrinkage and temporary or permanent dis-
appearance of the tumors.
LPS is well tolerated by rodents, dogs and cats [6], but
causes septic shock in humans [7]. Therefore we searched
for an effective TLR agonist that would be safe for humans
and shows strong synergy with phagocytosis stimulating li-
gands attached to tumor cells. Anchored mannan was se-
lected for the stimulation of phagocytosis, as it gave the
best results (mainly survival prolongation) in previous ex-
periments [4, 5]. Resiquimod (R-848) proved to be the best
TLR agonist demonstrating synergy with mannan anchored
to tumor cells. This innate immunity based cancer im-
munotherapy was further improved by our search to find
the optimal therapeutic mixture, concentration, and timing.
Methods
Chemicals
Tissue culture media and media supplements, mannan
(Saccharomyces cerevisiae), laminarin (Laminaria digi-
tata), Tris(2-carboxyethyl)phosphine hydrochloride
(TCEP), f-MLF (N-Formyl-methionyl-leucyl-phenylalan-
ine), epicatechin, polyinosinic:polycytidylic acid, sodium
salt (poly (I:C)), lipopolysaccharide (LPS) from Escherichia
coli, TNF-alpha, and GM-CSF were obtained from Sigma-
Aldrich (St. Louis, USA). 4-(N-Maleimidomethyl) cyclo-
hexanecarboxylic-acid N-hydroxysuccinimide ester
(SMCC) was provided by Thermo Scientific (Erembode-
gem, Belgium). Biocompatible Anchor for cell Membrane
(BAM, Mw 4000) was obtained from NOF EUROPE
(Grobbendonk, Belgium). N-Formyl-methionyl-leucyl-
phenylalanine with two lysine molecules (f-MLFKK) was
synthesized by Schafer-N (Copenhagen, Denmark). Imi-
quimod (R-837) was delivered by Merck Millipore
(Billerica, USA), monophosphoryl lipid A (MPLA) by
Avanti Polar Lipids (Alabaster, USA), and resiquimod (R-
848) by Tocris Bioscience (Bristol, UK).
Cell lines, bacteria and mice
Murine melanoma B16-F10 cells were purchased from
American Type Culture Collection (ATCC, Manassas,
VA) and were cultivated in RPMI 1640 (Sigma-Aldrich,
USA) supplemented with 10% fetal calf serum (FCS, PAA,
Austria) and antibiotics. Cells were maintained at 37 °C in
a humidified atmosphere with 5% carbon dioxide.
Heat killed Listeria monocytogenes was purchased
from InvivoGen (Toulouse, France). SPF C57BL/6
mice (female, 18–20 g) were obtained from Charles
River Laboratories (Sulzfeld, Germany). Mice were
housed in barrier facilities with free access to sterile
food and water. Photoperiod was 12/12, temperature
22 °C. All experimental mouse procedures were per-
formed in accordance with the laws of the Czech
Republic. Experimental project was approved by the
Ministry of Education, Youth and Sports (protocol no.
28842/2014-3).
Synthesis of mannan-BAM and f-MLFKK-BAM
First, aminated mannan was prepared by reductive amina-
tion according to Torosantucci et al. [8]. A mannan solu-
tion in an environment of ammonium acetate was reduced
by natrium cyanoborohydride at pH of 7.5 and 50 °C for 5
days. The solution was subsequently dialyzed (MWCO
3500 dialysis tubing, Serva, Heidelberg, Germany) against
PBS at 4 °C overnight. Peptide f-MLFKK already contained
an amino group required for binding of BAM.
Binding of BAM anchor on amino group of mannan
(f-MLFKK) was performed at pH of 7.3 [9]. During one
hour at room temperature, N-hydroxysuccinimide
(NHS) group of BAM reacted with amino group of man-
nan or with ε-amino group of lysine, respectively.
Synthesis of mannan-SMCC and Listeria monocytogenes-
SMCC. In vivo application
Binding of NHS group of heterobifunctional compound
SMCC to amino groups of aminated mannan and Lis-
teria monocytogenes was performed according to SMCC
manufacturer’s instructions (Thermo Scientific, Pierce
Protein Biology Products). Binding of mannan-SMCC or
Listeria monocytogenes-SMCC to tumor cells requires
the presence of –SH groups on these cells. Addition of
–SH groups on tumor cells was accomplished by the re-
duction of cystines as previously described [10]. A redu-
cing agent (50 mM solution of TCEP in PBS) was
injected intratumorally (i.t.) 1 h prior to application of
SMCC ligands. The injection of TCEP alone does not
have any effect on tumor growth [4].
Tumor transplantation
B16-F10 melanoma cells, suspended in serum free
RPMI 1640, were inoculated subcutaneously (s.c.) in
the previously shaved right flank of mice. Each mouse re-
ceived 4 × 105 melanoma cells in 0.1 ml of medium.
Treatment and evaluation of treatment
Randomization of mice in groups was performed 12 days
after transplantation of melanoma B16-F10 cells and was
immediately followed by initiation of therapies based on
intratumoral application of 50 microliters of correspond-
ing preparations (day 0). All mice were housed individu-
ally during therapy.
Tumor size was measured with callipers every other
day. Tumor volume was calculated, as previously de-
scribed [11], using the formula V = π/6 AB2; A = the lar-
gest dimension of tumor mass (length), B = the smallest
dimension of the tumor mass (height).
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Mean reduction of tumor growth (%)
The calculation of mean reduction of tumor growth was
performed as previously described [4]. After therapy
began, on days 4, 6, 8, 10, 12 and 14, the reduction of
tumor growth was calculated using the following
formula:
mean tumor volume in control group – mean tumor volume in treated groupð Þ x 100
mean tumor volume in control group
The average of calculated reductions in the indicated
days is regarded as “mean reduction of tumor growth”.
Analysis of cell infiltrate using flow cytometry. Cytokine
assay
Analysis of cell infiltrate was performed as previously de-
scribed [4]. Mice were euthanized via cervical dislocation,
and the tumors were excised. Subsequently, each tumor
was gently washed with cold RPMI 1640 medium, cut into
small pieces, and placed into 1 ml cold RPMI 1640 con-
taining 0.33 mg/ml Liberase DL and 0.2 mg/ml DNase I
(both Roche Diagnostics, Germany). After a 1 h incubation
on a rotary shaker at 37 °C, clumps of tissue aggregates
were centrifuged at 160 g for 10 min at 4 °C. Supernatant
was used to determine IFN-gamma and IL-10 using the
ELISA kit (eBioscience and LSBio, respectively), performed
according to manufacturers recommendations. The result-
ing pellet was gently passed through a plastic strainer
(70 μm, BD Biosciences, USA) into cold PBS (pH 7.3) and
washed by centrifugation at 160 g for 10 min at 4 °C. Cells
were then transferred into a 96-well plate (Corning Incor-
porated, USA) and analyzed by flow cytometry. Particular
leukocyte subtypes were determined using the following
monoclonal antibodies (eBioscience, USA): a) Total leuko-
cytes - anti-mouse CD45 PerCP-Cy5.5; clone 30-F11, b) T
cells - anti-mouse CD3e FITC; clone 145-2C11, c) CD4+ T
cells - anti-mouse CD4 APC; clone GK1.5, d) CD8+ T cells
- anti-mouse CD8a; clone 53–6.7, e) B cells - anti-mouse
CD19 APC; clone eBio1D3, f) NK cells - anti-mouse
NK1.1 PE; clone PK136, g) granulocytes (anti-mouse Ly-
6G (Gr-1) Alexa Fluor 700; clone RB6-8C5, h) macro-
phages - anti-mouse F4/80 Antigen PE-Cy7; clone BM8,
and i) dendritic cells - anti-Mouse CD11c PE; clone N418,
anti-Mouse MHCII (I-A/I-E) Alexa Fluor 700; clone M5/
114.15.2). Analysis was performed using a BD FACSCanto
II flow cytometer (BD Biosciences, USA), equipped with
two lasers (excitation capabilities at 488 nm and 633 nm).
BD FACSDiva software 6.1.3. was used for the analysis of
flow cytometry data.
Preparation and priming of neutrophils
Neutrophils were isolated from murine bone marrow ac-
cording to Stassen et al. [12] and subsequently purified
using MACS technique (Miltenyi Biotec). Purity was
checked by BD FACSCanto II flow cytometer (BD
Biosciences, USA) using anti-mouse CD45 APC, Clone: 30-
F11 and anti-mouse Ly-6G (Gr-1) Alexa Fluor 700, Clone:
RB6-8C5 antibodies (eBioscience). Neutrophils were
primed according to Dewas et al. [13] by the mixture of
GM-CSF and TNF-alpha (12 ng and 2.5 ng/ml respectively)
for 20 min. The priming solution was enriched with 2 mi-
cromolar solution of soluble beta glucan (laminarin) as pre-
viously described [5]. Experiments were performed in
complement containing medium (FCS was not heat
inactivated).
Statistical analysis
Statistical analysis was performed using one-way
ANOVA with Tukey’s post hoc test and Log-rank test,
respectively (STATISTICA 12, StatSoft, Inc., Tulsa, OK
74104, USA). Error bars indicate SEM.
Results
Searching for proper combination of TLR agonist and
phagocytosis stimulating ligand leading to effective
melanoma B16-F10 immunotherapy
The main goal of our study was to find proper TLR ago-
nist(s), which, in combination with phagocytosis stimu-
lating ligands, would result in tumor shrinkage and
elimination. Previously, we discovered that mannan at-
tached to tumor cells (hydrophobic BAM anchor or
SMCC) was a good stimulator of phagocytosis [4, 5].
Thus, we used this finding throughout the present study.
TLR ligand replacement was necessary due to the previ-
ously used LPS, a TLR4 agonist, which poses a danger-
ous threat to humans [4, 5]. Overall, three different TLR
agonists were tested as possible LPS replacements.
First, we tried monophosphoryl lipid A (MPLA) which
is an LPS derivative and TLR4 agonist with very low tox-
icity for humans. However, MPLA, mannan-BAM, or
their mixture, lead to only slight, non-significant tumor
growth reduction (Fig. 1). No signs of MPLA and
mannan-BAM synergy were observed. Similar results
were observed with the use of another tested compound,
TLR7 agonist imiquimod (R-837) (data not shown).
Resiquimod (R-848), a TLR7 agonist in mice and TLR7
and 8 agonists in humans, was likewise studied. The R-848
+mannan-BAM combination revealed a strong synergistic
effect resulting in 75.4% mean reduction of tumor growth
(Fig. 2a). As shown in Fig. 2b, mice treated with this com-
bination survived longer than PBS treated control group.
However, the difference was not statistically significant.
This experiment was repeated twice with similar results, in-
cluding the observation of more than 100 days survival.
Therapy based on combination of R-848 with anchored
f-MLF motif
The effect of therapeutics based on anchored mannan de-
pends on the presence of mannan binding lectin (MBL) in
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serum. As 5–10% of humans lack MBL, it is necessary to
have mannan independent therapeutic system. Therefore,
we tested the combination R-848 + f-MLFKK-BAM and
compared it to R-848 +mannan-BAM. Both mixtures
caused comparable reduction of tumor growth (Fig. 3).
Immunotherapy of melanoma B16-F10 based on the synergy
of R-848 and mannan-SMCC. Further improvement using
poly(I:C) and anchored L. monocytogenes
The combination of R-848 with anchored mannan
showed the best therapeutic effect from all studied
combinations. Thus, we focused on further improvement
of this therapy. Specifically, we tested a stronger binding
of mannan-SMCC (covalent binding) together with the
addition of other TLR agonists. Listeria monocytogenes,
a predominant agonist of TLR2, was added alone and/or
in the combination with TLR3 agonist poly(I:C). As
shown in Fig. 4a, the mixture of R-848 with mannan-
SMCC, resulted in strong inhibition of tumor growth.
Further addition of L. monocytogenes alone or in the
combination with poly(I:C) did not significantly improve
its therapeutic effect. The major effects of additives were
Fig. 1 Immunotherapy of melanoma B16-F10 using MPLA alone or in combination with mannan-BAM. C57BL/6 mice (females) were inoculated
subcutaneously in a shaved area of the right flank with 4 × 105 murine melanoma B16-F10 cells per mouse in 0.1 ml RPMI. Twelve days after
tumor transplantation, mice were randomized in groups of six. Therapies started immediately. The preparations were applied intratumorally (50
microliters/mouse) in pulse regime (days 0, 1, 2…8, 9, 10). After therapy commenced, mice were kept individually. Tumors were measured every
second day for 14 days and their volume was calculated. The composition of preparations used was: 0.5 mg MPLA/ml PBS, 0.5 mg MPLA/ml
0.2 mM mannan-BAM in PBS, 0.2 mM mannan-BAM in PBS, PBS
Fig. 2 Immunotherapy of melanoma B16-F10 based on the synergy of R-848 and mannan-BAM. The experimental design was the same as described
in Fig. 1. Six mice were used per group. The composition of therapeutic mixture was: 0.5 mg R-848, HCl form/ml PBS, 0.5 mg R-848, HCl form/ml
0.2 mM mannan-BAM in PBS, 0.2 mM mannan-BAM in PBS, PBS. a The effect of therapy on tumor growth. * P≤ 0.05 * * P≤ 0.005 * * * P≤ 0.0005
compared to control (PBS). o P≤ 0.05 o o P≤ 0.005 o o o P≤ 0.001 compared to mannan-BAM. b Survival analysis. a – R-848, b – R-848 +mannan-
BAM, c – mannan-BAM, d- PBS (control)
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observed in the survival experiments. As shown in
Fig. 4b, groups treated with L. monocytogenes exhibited
significantly higher survival rates than untreated groups.
An 83.3% survival rate was observed, independent of the
presence or absence of poly(I:C). Furthermore, all sur-
viving mice were re-transplanted again with B16-F10 on
day 120. As shown in Table 1, re-transplantation was
successful in one mouse in the group b and in two mice
in group d. This resulted in death of animals. In the
groups treated with the mixture containing poly(I:C) (c
and e), the mice were fully protected against re-
transplantation. All mice lived without any pathological
symptoms for more than 1 year after treatment.
Flow cytometry analysis of cell infiltrate in R-848 + poly(I:C)
+ L. monocytogenes-SMCC +mannan-SMCC melanoma
treatment. Cytokine assay
During the course of therapy with the complex thera-
peutic mixture (R-848 + poly(I:C) + L. monocytogenes-
SMCC +mannan-SMCC), which showed the best thera-
peutic effect in the previous experiment, we analyzed
tumor infiltrate from treated mice and compared it with
a PBS control. In treated group, a strong granulocytic in-
filtration was observed. In particular, infiltration was
higher between days 7 and 15, reaching statistical signifi-
cance on day 7 (Fig. 5a). Minor, but not significant, in-
crease of CD4+ Th lymphocytes was observed in the
treated group, which contrasts with the no change ob-
served in the control group (Fig. 5b). The levels of Tc
lymphocytes (CD8+) were low in both groups through-
out the monitored period (Fig. 5c). No dramatic changes
in the count of dendritic cells were observed. However, a
non-significant, higher quantity of these cells was ob-
served throughout the monitored period when com-
pared to the control group (Fig. 5d). No changes in B
lymphocyte, NK, and monocyte/macrophage counts
were observed.
Cytokines measurement revealed high levels of IFN-
gamma (Fig. 6a), low levels of IL-10 (Fig. 6b), and high
IFN-gamma/IL-10 ratio (Fig. 6c) in tumor environment
of treated mice indicating initiation of Th1 response.
At the beginning of the therapy, mean tumor volume
was 155.4 + −93.2 mm3. Analysis of tumor infiltrating
cells and cytokines was terminated on day 19 of treat-
ment, as 9 surviving mice were tumor free.
Interaction of neutrophils with opsonized tumor cells –
frustrated phagocytosis and oxidative burst
The role of phagocytes (granulocytes) in the herein
described cancer treatment approach based on artifi-
cial opsonization of tumor cells is supported in Fig. 5.
Depletion of neutrophils by Ly6G antibody reduced
the effect of R-848 + mannan-BAM therapy [unpub-
lished results]. An attempt of phagocytes (especially
neutrophils) to phagocyte relatively large melanoma
cells was described as a specific type of frustrated
phagocytosis [5, 14]. This idea was supported by the
estimation of the frequency of frustrated phagocytosis
events in neutrophil-melanoma interaction, observed
during in vitro experiments (Table 2). The key role of
mannan and f-MLF attachment to tumor cell surface
for the stimulation of frustrated phagocytosis was
demonstrated.
Frustrated phagocytosis is initiated by tight contact
between neutrophils and melanoma cells and is
followed by the release of granule content into the
pockets formed between neutrophils and tumor cells
[5, 14]. Granules contain components involved in
killing target melanoma cells either directly (hydro-
lases, defensins) or indirectly (myeloperoxidase
dependent HClO formation connected with oxidative
burst). We analyzed the cytotoxic effect of these
processes and the participation of oxidative burst
dependent mechanisms. The latter was analyzed
Fig. 3 Therapy based on the combination of R-848 with anchored f-MLF motif. The experimental design was the same as described in the Fig. 1. Six
mice were used per group. The composition of therapeutic mixture was: 0.5 mg R-848, HCl form/ml 0.2 mM mannan-BAM in PBS, 0.5 mg R-848, HCl
form/ml 0.5 mM f-MLFKK-BAM in PBS, PBS was used as a control. * P≤ 0.05 ** P≤ 0.005 *** P≤ 0.001 **** P≤ 0.0005 compared to control (PBS)
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Fig. 4 Immunotherapy of melanoma B16-F10 based on the synergy of R-848 and mannan-SMCC. Further improvement using poly(I:C) and anchored
L. monocytogenes. Tumor transplantation and measurement was performed as described in Fig. 1. Six mice were used per group. Therapies, based on
intratumoral application of corresponding preparations (50 microliters/mouse), started 12 days after tumor transplantation. Four therapeutic pulses
were applied on days 0, 1, 2…8, 9, 10…16, 17, 18…24, 25, 26. Therapeutic mixture contained following concentrations of active parts dissolved in PBS:
1 billion L. monocytogenes-SMCC/ml, 0.5 mg R-848, HCl form/ml, 0.5 mg poly(I:C)/ml, 0.2 mM mannan-SMCC, PBS was used as control. a The effect of
therapy on tumor growth. * P≤ 0.05 ** P≤ 0.01 *** P≤ 0.005 **** P≤ 0.001 ***** P≤ 0.0005 compared to control (PBS). b Survival analysis. a – L.m.-
SMCC +man-SMCC. b – L.m.-SMCC+ R-848 +man-SMCC. c – L.m.-SMCC+ R-848 + poly(I:C) +man-SMCC. d – R-848 +man-SMCC. e – R-848 + poly(I:C)
+man-SMCC. f – PBS (control). b versus f….. P≤ 0.005. c versus f….. P≤ 0.01. d versus f….. P≤ 0.05. e versus f….. P≤ 0.05
Table 1 Immunotherapy of melanoma B16-F10 based on the synergy of R-848 and mannan-SMCC. Further improvement using
poly(I:C) and anchored L. monocytogenes. Re-transplantation
Initial treatment Number of survived mice Group (see Fig. 4b) Number of successful re-transplantations
L. monocytogenes-SMCC + R-848 +mannan-SMCC 5 b 1
L. monocytogenes-SMCC + R-848 + poly(I:C) + mannan-SMCC 5 c 0
R-848 +mannan-SMCC 2 d 2
R-848 + poly(I:C) + mannan-SMCC 1 e 0
Re-transplantation of mice that survived in experiment shown in Fig. 4 was performed on day 120. All surviving mice were inoculated again with B16-F10 (4 × 105
melanoma cells/mouse s.c.)
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Fig. 5 Flow cytometry analysis of cell infiltrate in R-848 + poly(I:C) + L. monocytogenes-SMCC +mannan-SMCC melanoma treatment. The transplantation of
melanoma B16-F10 was performed as described in Fig. 1. Twelve days after tumor transplantation, mice were randomized in two groups of 24. Therapy
based on intratumoral application of corresponding therapeutic mixtures (50 microliters/mouse) started immediately. Four therapeutic pulses were applied
on days 0, 1, 2…8, 9, 10…16, 17, 18…24, 25, 26. The composition of therapeutic mixture was: 1 billion L. monocytogenes-SMCC + 0.5 mg R-848, HCl form
+ 0.5 mg poly(I:C)/ml 0.2 mM mannan-SMCC in PBS, PBS was used as a control. Three mice from each group were euthanized on days 3, 7, 11, 15, 19 after
the start of the therapy. Three mice were killed without any application at time 0 (negative control). The analysis of cell infiltrate of excised tumors was
performed using flow cytometry and expressed as cells/mm3 of tumor mass. The following labeled antibodies were used: a anti-mouse Ly-6G (Gr-1) Alexa
Fluor 700 (granulocyte detection), b anti-mouse CD4 APC; clone GK1.5 (CD4+ Th lymphocytes), c anti-mouse CD8a; clone 53–6.7 (CD8+ Tc lymphocytes),
d anti-Mouse CD11c PE; clone N418, anti-Mouse MHCII (I-A/I-E) Alexa Fluor 700; clone M5/114.15.2 (dendritic cells). * P≤ 0.05 compared to control (PBS)
Fig. 6 R-848 + poly(I:C) + L. monocytogenes-SMCC +mannan-SMCC melanoma treatment. Cytokine assay. After separation of cells from tumors excised in
previous experiment (Fig. 5), cytokine analysis of corresponding supernatants was performed: a IFN-gamma, b IL-10, c calculated ratio of IFN-gamma/IL-10
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using epicatechin - an inhibitor of oxidative burst.
As shown in Fig. 7a, neutrophils killed 50% of op-
sonized melanoma cells and the inhibition of oxida-
tive burst resulted in 50% reduction of cytotoxicity.
This result supports the hypothesis that oxidative
burst participates on cytotoxic effects resulting from
the frustrated phagocytosis.
Neither melanoma cells (Fig. 7a) nor neutrophils
(Fig. 7b) were directly affected by epicatechin alone.
Discussion
Our previous study demonstrated that TLR agonists
combined with phagocytic receptors ligands may act as
an effective cancer therapy [4, 5]. In the present follow-
up study, we focused on searching for ligands that could
be applied in humans. To stimulate phagocytosis, man-
nan was attached to tumor cells either covalently by an
SMCC anchor or through a hydrophobic BAM anchor.
As we described previously, mannan stimulates MBL-
dependent phagocytosis, which kills tumor cells [4, 5].
This is based on the initiation of the lectin pathway of
complement activation with MBL-mannan complex,
leading to iC3b opsonization of target cells.
The TLR4 agonist LPS, which was used in our previ-
ous studies [4, 5] cannot be utilized in humans due to
the risk of developing septic shock. We tested several
possible replacement compounds, the first being MPLA,
a low-toxicity derivate of the lipid A region of LPS [15].
MPLA alone showed only negligible effect on tumor
growth. When combined with mannan, no synergy re-
sulted. Mata-Haro and colleagues [16] reported that low
toxicity of MPLA, in comparison to LPS, is caused by
the active suppression of pro-inflammatory activity. This
could explain the failure of MPLA +mannan-BAM
Table 2 Interactions between neutrophils and melanoma cells
with or without anchored ligands of phagocytic receptors
Mean count of neutrophils attached to one melanoma
cell by mechanism of frustrated phagocytosis
Ligand 20 min. 30 min. 40 min.
Mannan-BAM 0.333 0.556 0.733
Mannan free 0.111 0.000 0.000
f-MLFKK-BAM 0.589 0.311 0.360
f-MLF free 0.480 0.111 0.000
PBS (control) 0.000 0.000 0.000
B16-F10 melanoma cells were incubated (30 min, 37 °C) with 0.02 mM
mannan-BAM or 0.05 mM f-MLFKK-BAM in culture medium and then
subsequently washed. Suspension of bone marrow neutrophils (90% purity)
primed with GM-CSF + TNF-alpha (+ laminarin in case of mannan-BAM) in culture
medium was added to B16-F10 cells. Free ligands were added in a concentration
of 0.02 mM (mannan) and 0.05 mM (f-MLFKK). Neutrophils and melanoma cells
were incubated at a 2:1 ratio
The rate of frustrated phagocytosis events was estimated by light microscopy:
Frustrated phagocytosis was defined as neutrophil/melanoma cell contact, where
neutrophil adhere tightly to B16-F10 cell. Such contact is further characterized by
neutrophil flattening and gaining of waning moon shape [5]
Fig. 7 The interaction of neutrophils with opsonized melanoma cells. Oxidative burst. B16-F10 melanoma cells were incubated (30 min, 37 °C) with
0.02 mM mannan-BAM in culture medium and subsequently washed. The suspension of bone marrow neutrophils (90% purity), primed with GM-CSF
+ TNF-alpha + laminarin in culture medium was added to B16-F10 (both free and mannan-BAM covered) in the ratio 5:1. Where indicated, 0.1 mM
epicatechin was added. All mixtures were incubated for 2 hours at 37 °C. After the incubation, living, trypan blue excluding melanoma cells (a) and
neutrophils (b) were counted with a haemocytometer. *P≤ 0.05 compared to B16-F10 + epicatechin. oP≤ 0.005 compared to B1-F10. ■P≤ 0.0005
compared to B16-F10 + epicatechin. ¤P≤ 0.005 compared to mannan-BAM covered B16-F10. xP≤ 0.05 compared to B16-F10 + neutrophils
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therapy, as infiltration of inflammatory cells is crucial
for the presented therapy [4, 5].
R-837, another TLR agonist, has been shown to induce
an anti-tumor immune response and is being used to treat
skin tumors [17]. However, in our experiments, R-837
only exhibited a weak effect, and was thus not involved in
further treatments. An explanation for the insufficient im-
pact of R-837 on tumor cells could be that it induces less
pronounced production of cytokines and enhancement of
cellular immunity than R-848, for a review see [18].
The last tested LPS replacement substance was R-848.
R-848 alone caused visible, but not statistically signifi-
cant tumor growth reduction. Complete recovery was
not observed. However, R-848 combined with anchored
mannan resulted in significant synergy and partial recov-
ery of treated mice. Regarding the mechanisms of action,
we are considering the important role of granulocytes
(neutrophils), as their strong infiltration was noticed. In
our previous in vitro experiments, we observed a signifi-
cant cytotoxic effect of neutrophils against the tumor
cells opsonized with mannan. These tumor cells were
killed by frustrated phagocytosis [5]. In herein present
study, we confirmed our previous observations and by
using epicatechin, revealed significant participation of
oxidative burst in killing mechanisms.
The synergy between R-848 and anchored mannan corre-
sponds to our therapeutic concept based on inflammatory
infiltration of tumors and the direction of recruited phago-
cytes to opsonized tumor cells [4, 5]. Ensuring proper
timing of drug delivery is vital for an effective therapy. For
R-848 +mannan based therapies we used the same pulse
regime as previously described [4]. The optimal therapeutic
scheme corresponds well with the observation from Bour-
quin et al. [19], who based their tumor treatment strategy
on the repeating cycles of R-848 injections, separated by
treatment-free intervals. Treatment free intervals are neces-
sary for the recovery of sensitivity to R-848. R-848, like
other TLR agonists, induces TLR tolerance, which should
be circumvented by proper timing of therapy [20, 21].
The induction of synthesis of pro-inflammatory cyto-
kines in the tumor environment is important for the
recruitment of inflammatory cells. Simultaneously, con-
ditions for the shift of tumor-associated macrophages
(TAMs) towards an anti-tumor, pro-inflammatory M1
phenotype and reduction of the activity of tumor pro-
tecting immunosuppressive T regulatory lymphocytes
(Tregs) and myeloid derived suppressor cells (MDSC)
are created [22]. The direct effect of R-848 on MDSC
count reduction [23] and the stimulation of phagocytic
activity of infiltrating cells by TLR agonists should be
taken into account [24].
R-848 also induces the maturation of plasmacytoid den-
dritic cells (pDC) [25] and promotes the production of
antibodies [26]. R-848 was described as potential vaccine
adjuvant enhancing Th1 response in mice [27]. Further-
more, R-848 also had a direct effect on tumor cells - it
upregulates the expression of opioid growth factor recep-
tor, which leads to the anti-proliferative and cancer sup-
pressive effects, independent of immune function [28]. All
these mechanisms can contribute to the effect of therapy.
Since a small percentage of humans are MBL deficient,
f-MLF was tested as an alternative ligand of phagocytic
receptors. When anchored, f-MLF was able to stimulate
phagocytosis and kill tumor cells [5]. Positive results of
the treatment with R-848 + anchored f-MLF supported
the possibility of using this ligand for the treatment of
patients with an MBL deficiency.
To enhance the effect of R-848 +mannan based therapy,
we tested the the effects of adding of heat killed L. monocy-
togenes into the treatment mixture. Introduction of L.
monocytogenes did not accelerate the shrinkage of tumors,
but had a strong effect on survival rate of mice. Heat killed
L. monocytogenes is able to induce Th1-dominated immune
response [29]. We hypothesize that cell-mediated adaptive
immunity joined the innate immune response and elimi-
nated the remaining melanoma cells. This is supported by
the observed Th1 response initiation. Moreover, 80% of
mice were protected against re-transplantation of melan-
oma cells, which suggests that acquired immunity response
was directed against melanoma specific antigens and that
tumor antigen-specific memory cells were involved.
The addition of poly(I:C) into the therapeutic mixture
(with and without L. monocytogenes) also increased the re-
sistance of treated mice against re-transplantation.
Poly(I:C) works in synergy with R-848 at the level of stimu-
lation of pro-inflammatory cytokines synthesis [30, 31] and
is frequently used as vaccine adjuvant. Additionally,
poly(I:C) stimulates both human [32] and murine [33] den-
dritic cells maturation, so it can enhance antigen presenta-
tion to the cells of adaptive immunity.
Survival of all treated mice for more than 1 year after
treatment serves as indirect proof that the presented
combined therapy (L. monocytogenes + R-848 + poly(I:C)
+mannan-SMCC) may eliminate metastases as well, be-
cause B16-F10 tumors metastasize very early (before the
day 10 after transplantation as described by Wald et al.
[34], i.e. prior to the initiation of our therapy). However,
this aspect needs further investigation.
In summary, we have demonstrated the strong thera-
peutic effect when the TLR agonist R-848 is combined
with anchoring mannan to the tumor cells. This effect was
further enhanced by addition of another TLR agonists
(poly(I:C), L. monocytogenes) into the therapeutic mixture.
Innate immunity cells, particularly neutrophils, seem to
play a key role in the presented treatment mechanism.
Evaluating the role of adaptive immunity in the above
described therapy will be the main goal as we continue
our research.
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Conclusions
Therapy based on R-848 +mannan-SMCC with support-
ive L. monocytogenes and poly(I:C) is much too complex
to provide a detailed description of all involved mecha-
nisms. Nevertheless, the acting components play import-
ant roles and perform in synergy. We assume that this
therapy can be used for cancer treatment in humans, as
the majority of the components in the therapeutic mix-
ture have already been used or tested in clinical trials.
The presented treatment of fast growing, aggressive and
low immunogenic B16-F10 melanoma, represent a base
for promising future research in the field of human can-
cer immunotherapy.
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